Q2 25 EPS
$-2.40
MISS 71.55%
Est. $-1.40
Q2 25 Revenue
$892,000
MISS 86.15%
Est. $6.4M
vs S&P Since Q2 25
-18.0%
TRAILING MARKET
CRSP -1.2% vs S&P +16.8%
Market Reaction
Did CRSP Beat Earnings? Q2 2025 Results
CRISPR Therapeutics delivered a sharply disappointing second quarter, posting a loss of $2.40 per diluted share against a consensus estimate of $1.40, a miss of 71.55%, while revenue of $892,000 fell 86.15% short of the $6.44 million analysts had exp… Read more CRISPR Therapeutics delivered a sharply disappointing second quarter, posting a loss of $2.40 per diluted share against a consensus estimate of $1.40, a miss of 71.55%, while revenue of $892,000 fell 86.15% short of the $6.44 million analysts had expected, though that modest top line still represented 72.5% growth year over year. The single largest driver of the quarter's wider loss was a $96.25 million charge for acquired in-process R&D tied to a new collaboration with Sirius Therapeutics on siRNA therapies, pushing the total net loss to $208.55 million. The results sent shares lower, even as the company pointed to accelerating momentum in its CASGEVY gene therapy launch, with 16 patient infusions completed in Q2 alone and reimbursement secured in 10 countries. Looking ahead, CRISPR expects complete Phase 1 data for its cardiovascular candidate CTX310, which has shown up to 82% triglyceride reductions, to be presented at a medical meeting in the second half of 2025, with additional pipeline updates for CTX112 and CTX131 also expected before year-end.
Key Takeaways
- • CASGEVY commercial ramp: 75+ ATCs activated globally, ~115 patients completed cell collection, 29 infused including 16 in Q2 2025
- • Reimbursement access secured in 10 countries for CASGEVY
- • Encouraging dose-dependent efficacy data from CTX310 Phase 1 trial
- • Expansion into siRNA modality via Sirius Therapeutics collaboration
CRSP YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
CRSP Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are entering the second half of the year with momentum across both our commercial and clinical programs. The activation of 75 authorized treatment centers for CASGEVY has been achieved, marking a meaningful step in expanding patient access, while clinical trials across multiple other programs continue to advance. Looking ahead, we expect several key milestones including the presentation of complete Phase 1 data for CTX310, as well as updates across our oncology and autoimmune portfolios. Our focus remains on delivering transformative therapies for patients with critical unmet needs.”
— Samarth Kulkarni, Q2 2025 Earnings Press Release
CRSP Earnings Trends
CRSP vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CRSP EPS Trend
Earnings per share: estimate vs actual
CRSP Revenue Trend
Quarterly revenue: estimate vs actual
CRSP Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-1.23 | $-1.28 | -3.68% | $1.5M | -65.73% |
| Q4 25 MISS FY | $-1.23 | $-1.37 | -11.67% | $864,000 | -78.51% |
| FY Full Year | $-6.17 | $-6.47 | -4.91% | $3.5M | -42.66% |
| Q3 25 BEAT | $-1.29 | $-1.17 | +9.23% | $889,000 | -90.07% |
| Q2 25 MISS | $-1.40 | $-2.40 | -71.55% | $892,000 | -86.15% |
| Q1 25 MISS | $-1.28 | $-1.58 | -23.75% | $865,000 | -85.50% |